Status:
TERMINATED
MRS and Medication Response: A Pilot Study
Lead Sponsor:
Stanford University
Conditions:
Major Depressive Disorder
Major Depressive Episode
Eligibility:
All Genders
21-75 years
Brief Summary
We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed patients.
Detailed Description
The primary objective of this study is to demonstrate that it is feasible to image paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) brain concentrations using MRS technology in depr...
Eligibility Criteria
Inclusion
- Major depressive disorder:
- Inclusion Criteria:
- DSM diagnosis of Major Depressive Disorder
- Taking paroxetine \[(Paxil) or citalopram (Celexa) or escitalopram (Lexapro)\]for at least 6 weeks
- Between 21 - 75 years of age.
- Taking a stable dose of paroxetine \[(Paxil) or citalopram (Celexa) or escitalopram (Lexapro)\] for at least the 2 weeks prior to the imaging session
- Healthy controls:
- Between 21 - 75 years of age.
- Have a 21-item HAM-D score of less than or equal to 5.
- No current, or history of any Axis I disorder.
- Identify exclusion criteria.
- Exclusion criteria are as follows:
- Contraindications for an MRI exam. These includes biomedical devices such as pacemakers, aneurysm clips, prostheses, and other metallic objects embedded in the body such as bullets, buckshot, shrapnel, and any metal fragments from working around metal.
- Current pregnancy or lactation.
- Patients with claustrophobia.
- History, or current Axis I or Axis II disorders
- Active unstable medical problems, as confirmed by screening procedures
- Diagnosed with any autoimmune disease, (e.g., rheumatoid arthritis, Lupus, MLS).
- Chronic use of steroids or opiates.
- Positive urine toxicology screen for illicit substances of abuse.
Exclusion
Key Trial Info
Start Date :
August 6 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2020
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT03254342
Start Date
August 6 2013
End Date
August 31 2020
Last Update
August 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Psychiatry and Biobehavioral Sciences
Stanford, California, United States, 94305